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Diabetes Mellitus: 
Diabetes Mellitus is a condition that results in elevated blood glucose levels 
(hyperglycaemia); continued elevation can contribute to progressive micro and macro 
vascular complications leading to renal, nerve and ocular damage, representing a 
significant contributor to morbidity and mortality (Bilous, Donnelly & Williams, 2010). 
463 million people world-wide are living with diabetes mellitus; the UK population 
prevalence is 5.6% in adults aged 20-79 years (IDF, 2019). The estimated population 
prevalence of diagnosed and undiagnosed cases in England is approximately 8.5%; 
(PHE, 2020). Currently there are over 3.8 million people diagnosed with diabetes in 
the UK; approximately 1/15 people have diabetes. Over a million people are unaware 
they have the disease (Diabetes UK, 2019) 
Type 1 Diabetes Mellitus (T1DM) and other, rarer sub-types represent approximately 
10% of cases. The origin of the condition being autoimmune in nature, arising from the 
complete destruction of insulin secreting beta cells within the pancreas. Type 2 
diabetes Mellitus (T2DM) accounts for the remaining 90% of cases and results from 
the reduced effective action of insulin. This eventually leads to insufficient levels of 
insulin production, needed to sustain appropriate blood glucose levels. T2DM is 
caused by a combination of genetic and ethnic predispositions, but predominantly 
lifestyle factors such as obesity and lack of physical exercise. Incidence is further 
correlated with increasing age (Holt, Kumar & Watkins, 2015).  
This article will:  
• Introduce Type 1 and 2 Diabetes Mellitus 
• Support your understanding of how the human body regulates blood glucose 
• Identify correct blood glucose ranges and those which may give cause for concern 
• Give rationale to the importance of blood glucose monitoring as a fundamental 
procedure for people living with diabetes 
• Recognise how to measure blood glucose accurately 
• Provide a ‘how to’ guide on monitoring blood glucose using a glucometer   
• Gain insight into self-monitoring of blood glucose and developing technologies 
• Use contemporary evidence-based practice to underpin blood glucose monitoring 
practice 
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Gestational diabetes mellitus (GDM) manifests with a degree of glucose intolerance 
with onset or first recognition in pregnancy. Individuals affected by GDM have an 
increased risk of developing type 2 diabetes after pregnancy (Buchanan et al, 2007). 
There are several rarer subtypes of diabetes outside T1DM, T2DM and GDM, 
including but not limited to genetic defects leading to diabetes, idiopathic diabetes 
(presenting with no underlying autoimmune cause), endocrinopathies, or drug and 
chemical induced diabetes. For these reasons, and the potentially mixed picture of 
diagnosis, it is less important to label the type of diabetes than it is to understand the 
mechanisms and importance of hyper and hypo glycaemia and treat accordingly 
(American Diabetes Association, 2013).  
Rationale:  
The measurement of blood glucose provides information on the effectiveness of blood 
glucose metabolism and guides interventions to achieve optimal glucose control within 
the body.  
Glucose is a monosaccharide and is an essential fuel for the brain and other body 
cells formed as an end product of carbohydrate digestion (Maughan, 2008). Glucose 
is either metabolised to produce energy or is stored in the muscles and liver as 
glycogen. Changes in glucose level after absorption of carbohydrate is termed the 
‘glycaemic response’ (Sanders, 2016; Maughan, 2008). Regulation of normal glucose 
metabolism is shown in Figure 1.  
The measurement of blood glucose is a key self-care activity for people with diabetes 
and has been shown to positively correlate with improved long –term glycaemic control 
(Shaji et al 2013; Shrivastava, Shrivastava and Ramasamy, 2013) and can function 
as a cue to action in diabetes self-management (Brackney, 2018).     
The measurement of blood glucose is an essential component of care for individuals:  
• With T1DM and T2DM 
• People with diabetes who have recently commenced or changed dosages of 
medication to increase insulin levels 
• People with diabetes undergoing surgery 
• People who are acutely sick  
• In an emergency where consciousness level may be affected by low blood 
glucose (adapted from Delves-Yates, 2018a) 
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Figure 1: Regulation of normal glucose metabolism  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reference: Adapted from Boore et al, (2018) 
 
 
 
 
 
 
 
 
 
 
Target blood glucose ranges 
Normal target ranges:  
• Fasting plasma glucose level of 5-7 mmol/litre and 
Blood glucose in 
normal range           
(4.0 – 7.8 mmol/l) 
Insulin released from 
pancreas 
Glucose enters cells and 
increases metabolism. Glucose 
stored in liver as glycogen 
Blood glucose levels 
fall 
Blood glucose level 
rises 
Blood glucose levels 
rise 
Glycogen broken down into 
glucose. Glucose released into 
blood from liver 
Glucagon released 
from the pancreas 
Blood glucose levels 
fall 
Learning Point:  
Type 1 diabetes results in an absolute absence of insulin therefore blood glucose levels continue to 
rise because glucose cannot enter cells to be metabolised and produce energy; excess glucose 
cannot be stored as glycogen. These individuals require insulin injections every day. 
 
Type 2 diabetes causes cells to be less responsive to insulin and/or reduces insulin production by 
the pancreas; therefore, glucose entry into the cell is reduced resulting in increased blood glucose 
levels. Individuals may take medications to increase insulin production, to make cells more receptive 
to insulin or ultimately, may require injectable insulin 
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• Plasma glucose level of 4-7 mmol/litre before meals at other times of day 
(NICE, 2015a) 
Hyperglycaemia:  
• Random plasma glucose of more than 11 mmol/litre (NICE, 2015b) 
Hyperglycaemia describes any blood glucose concentration that is higher than 
recognised target ranges (Patton and Thibodeau, 2015). Prolonged hyperglycaemia 
can result in damage to many organs of the body leading to renal failure, blindness or 
gangrene resulting in amputation (Boore, Cook and Shepherd, 2018).  
Acute hyperglycaemia occurs when the body cannot utilise glucose due to insufficient 
or complete lack of insulin production. This causes the body to generate glucose via 
glycogenolysis (glycogen breakdown), lipolysis (fat breakdown) and gluconeogenesis 
(glucose derived from substrates such as lactate, glycerol and glucogenic amino 
acids). Blood glucose rises further, the person is effectively ‘starving in a sea of plenty’ 
(Dean et al, 2004). Fatty acid metabolites know as ketone bodies, accumulate from 
this process, resulting in Ketoacidosis. Ketones are observed in the blood and urine 
(Marieb and Hoehn, 2015; Patton and Thibodeau 2015). Symptoms of hyperglycaemia 
are summarised in table 1.  
Causes:                                                      
• Inadequate doses of insulin 
• Infection 
• Stress 
• Surgery 
• Medications (steroids, benzodiazepines)  
• Various in nutritional intake 
• Individuals receiving enteral / parenteral feeding  
• Critical illness 
(Marieb and Hoehn, 2015)    
Table 1: Symptoms  
Gastrointestinal  Nausea 
Vomiting 
Abdominal pain 
Hunger 
Adrenergic ‘Fight or flight response’ 
 
Respiratory Tachypnoea 
Renal  Glycosuria (excess glucose in urine) 
Polyuria (and dehydration) 
Polydipsia  
Electrolyte imbalance Excess ketones (from fat metabolism) 
5 
Revision for Practice Nursing – January 2020 
Hypokalaemia 
Hyponatraemia 
 
Liver and adipose tissue Acetone breath 
Cardiovascular Cardiac irregularities 
Central Nervous System CNS depression – drowsiness  
Coma 
(Adapted from Marieb and Kohen, 2015; Holt, Kumar and Watkins, 2015) 
 
 
 
 
 
 
                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
Hypoglycaemia:  
• Random plasma glucose of less than 4 mmol/litre  
Hypoglycaemia occurs when blood glucose levels fall resulting in inadequate energy 
available to the brain leading to abnormal behaviour - sometimes mistaken for 
Learning Point: Diabetic Ketoacidosis (DKA) 
• DKA results from severe hyperglycaemia and is a potentially life-threatening medical 
emergency 
• DKA requires high intensity nursing within high dependency / critical care units 
• In DKA urine will test positive for ketones and plasma ketones will be elevated  
• DKA requires urgent hospital treatment with insulin, fluid and usually potassium 
replacement 
• DKA leads to electrolyte imbalance due to excessive acidosis therefore close 
monitoring of electrolytes is required 
• DKA may be the presenting feature of newly diagnosed T1DM  
(Holt, Kumar and Watkins, 2015) 
Learning Point: Hyperosmolar Hyperglycaemic Syndrome (HHS) 
• HSS presents as extreme levels of hyperglycaemia without 
significant acidosis or ketones in people with T2DM (>40 mmol/l) 
• Ketones may not be present as people with T2DM may still produce 
low levels of insulin 
• May develop over weeks due to illness or dehydration 
• Management is similar to that of DKA although less likely to require 
potassium replacement but may need sub cut heparin to prevent 
thrombotic complications 
• Carries a higher mortality rate than DKA 
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drunkenness (Patton and Thibodeau, 2015). If prolonged the individual may lose 
consciousness and if not treated may die (Boore, Cook and Shepherd, 2018) 
 
 
 
 
 
 
 
 
 
The symptoms of hypoglycaemia are outlined in table 2.  
Causes:  
• Inadvertent insulin or sulphonylurea overdose (sulphonylureas work by 
increasing endogenous insulin production in the person with type 2 diabetes) 
or in response to a recent change in dose  
• Missed or inadequate meal 
• Unexpected exercise 
• Error in timing of dosage 
 
Table 2: Symptoms  
Central nervous system  • Headache 
• Confusion 
• Concentration difficulties 
• Changes is personality 
Cardiovascular • Palpitations 
Gastrointestinal • Hunger 
• Nausea 
• Belching 
Adrenergic • Sweating  
• Anxiety 
(Holt, Kumar & Watkins, 2015) 
 
 
 
STOP 
 and think:  
4 is the floor 
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Hypoglycaemia treatment (NICE, 2018):  
Mild – moderate hypoglycaemia:  
• 10-20g glucose given by mouth either in liquid form (such as GlucoGel®) or as 
granulated sugar / sugar lumps / 4-5 Jelly Babies 
• Repeat after 10-15 minutes 
• After initial treatment a snack providing sustained carbohydrate release will 
minimise rebound hypoglycaemia 
o Alternatively:  
▪ 10g of glucose is obtained from 2 teaspoons of sugar / 3 sugar 
lumps and also from non-diet drinks i.e.: 100ml Coca-Cola®.  Note 
that the carbohydrate content of some glucose drinks is currently 
subject to change – check the label 
Severe hypoglycaemia (causing unconsciousness):  
• Glucagon can be given by injection, which increases plasma glucose by 
mobilising glycogen stored in the liver.  
• Give carbohydrate as soon as possible to restore liver glycogen stores 
• Glucagon may be prescribed for use in an emergency.  
• Alternatively, 20% glucose intravenous infusion can be given via a large gauge 
needle. 10% glucose may also be used. 50% glucose is not recommended due 
to potential extravasation injury.  
• Blood glucose should be monitored closely, especially if there has been an 
overdose with long acting insulin or is due to an oral antidiabetic drug as 
hypoglycaemic effects may persist for many hours. 
It is important to note that people with T1DM may become increasingly unaware that 
they are experiencing a hypoglycaemic episode, as the number of episodes they 
experience increases. This is termed ‘hypo unawareness’. People with T1DM should 
be assessed for their awareness of hypoglycaemia at each annual review with their 
doctor (NICE, 2015a).  
15 Healthcare Essentials for People Living with Diabetes 
Diabetes UK (2020a) highlight the importance of the 15 essential healthcare checks 
for people living with diabetes. Ensuring people living with diabetes receive theses 
checks in community practice and at specialist diabetes centres, reduces the risk of 
serious diabetic complications such as diabetic retinopathy, neuropathy and foot 
complications. The 15 healthcare essentials include:  
1. HbA1c testing 
2. Blood pressure measurement 
3. Cholesterol testing 
4. Retinal screening 
5. Foot and leg check 
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6. Renal function testing 
7. Advice on diet 
8. Emotional and psychological support 
9. Diabetes education course such as DAFNE (type 1) or DESMOND 
(type 2) 
10. Care from diabetes specialists if required 
11. Free flu vaccination 
12. High quality diabetes care if requiring hospital admission 
13. Support with sexual dysfunction 
14. Smoking cessation advice 
15. Specialist care for conception planning 
 
Self-monitoring of blood glucose (SMBG) – finger-prick testing:  
Within the community setting routine self-monitoring of blood glucose levels is advised 
for all people with T1DM, ideally at least 4 times per day; before each meal and before 
bed (NICE, 2015a). People with T2DM can also self-monitor blood glucose if they 
require insulin, have evidence of hypoglycaemia, or if pregnant or planning pregnancy 
(NICE, 2015c).  Frequency of blood glucose testing does vary between individuals and 
each person will have their own routine with regards to timing of testing. Further 
adjustments to testing frequency may be required following changes in medications / 
dosing or intercurrent illness which may give rise to problematic glycaemic control.  
Consideration should be given when people who routinely monitor their own blood 
glucose are admitted to hospital. There is conflicting evidence as to the continuation 
of self-monitoring in the in-patient setting. Whilst some authors highlight the complexity 
of hospital treatment and its effect on normal glucose control as a factor which makes 
self-monitoring beyond the ability of the individual to manage their own blood glucose 
(Shah and Rushakoff, 2015); others counter this argument highlighting that removing 
self-monitoring may place the person at increased risk of hypo or hyperglycaemia 
(Mabrey and Setji, 2015).  
However, there is consensus that cooperative management and partnership with 
people with diabetes should be encouraged to maximise satisfaction, patient 
empowerment and clinical outcome.  
Equipment:  
• Blood glucose meter 
• Single use lancet 
• Test strips 
• Cotton wool / low linting gauze 
• Sharps box 
(Adapted from Delves-Yates 2018b) 
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Table 3 outlines the correct procedure for people with diabetes to perform blood 
glucose monitoring.  
Table 3: ‘How to’ perform SMBG finger prick testing  
Step Procedure Rationale 
1 Turn on the machine and ensure correct 
date and time are displayed and that there is 
adequate battery.  
• To ensure safety 
• To ensure accuracy of 
result recorded 
2 Ensure the unit of measurement is mmol/L • To ensure accurate 
measurement 
3 Ensure equipment set up, this may vary 
according to the device or if automated 
systems are used. Always follow 
manufacturer guidelines and local policy. 
Checks may include: 
• Test strips are in date and have not 
been left exposed to air 
• The monitor and strips are calibrated 
together 
• Any quality control testing is checked 
and carried out if required  
• The screen and display are intact  
• To minimise failure of 
device / equipment 
4 Selection of appropriate site, consider:  
• Skin condition – site should be well 
perfused and free of callouses 
• Avoid burns, cuts, scars, bruises, 
rashes 
• Avoid areas that have been subject to 
continual testing 
• Usual sites include the distal segment 
of the 3rd or 4th finger 
• Rotating sites and 
avoiding previous 
puncture areas 
reduces soreness and 
callous formation 
• Tips, pads of fingers 
and the index finger 
should be avoided as 
they have a dense 
supply of nerve 
endings and testing 
may be more painful 
5 Person should wash hands with soap and 
water and dry  
• Removes any 
contaminant which 
may give misleading 
readings 
6 Ensure the correct setting is used if depth 
setting can be adjusted on the lancet 
• Single use lancets 
minimise cross 
contamination and 
limit needle stick 
injury 
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• Adjusting the depth 
setting ensures 
minimal discomfort 
7 Remove the lancet device cap if present; 
activate the lancet as per manufacturer’s 
guidance at the selected site. Utilise the side 
of the finger. Rotate sites 
Single use devices should be used in the in-
patient setting to avoid cross contamination. 
In the persons own environment a reusable 
device may be used 
If there is difficulty obtaining the blood 
sample, ‘milking’ from the palm of the hand 
will increase droplet size, do not milk the 
finger alone 
• The side of the finger 
is less sensitive and is 
easier to obtain blood 
from 
• Sites are rotated to 
avoid infection, 
callous formation and 
to minimise pain 
• Milking the finger 
alone can cause 
contamination of the 
sample by interstitial 
fluid leading to a low 
reading 
8 Dispose of the lancet as required with 
regard to correct disposal of sharps within 
the relevant setting 
• To minimise cross 
contamination 
• To minimise risk of 
sharp injury 
9 Insert the test strip into the blood glucose 
meter. Ensure meter is ready for droplet. 
Apply the first drop of blood and ensure the 
window is entirely covered with blood 
• Inadequately filled 
strips leads to 
inaccurate results or 
error reports 
10 Apply gauze and pressure to puncture site, 
monitor for excessive bleeding 
• To ensure safety 
• To minimise bleeding 
11 Person should document results on a paper 
record. Alternatively, some smart meters 
can facilitate the downloading of blood 
glucose data 
• To ensure accurate 
record keeping 
12 The person should be encourage to act on 
any results outside of their own, 
individualised normal range. Adjustments in 
insulin dosing / medications may be 
required. Individuals should  seek help / 
contact their care team immediately if there 
is significant hyper / hypo glycaemia or 
indeed if blood glucose trends are 
persistently problematic.  
• To ensure changes in 
blood glucose are 
treated appropriately 
to maximise 
glycaemic control 
Reference: Adapted from Dougherty and Lister (2015) 
Errors in results:  
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Potential sources of error include:  
• Incorrect meter calibration 
• Poor meter maintenance 
• Incorrect operator technique 
• Inadequate quantity of blood on test strip (gives false low readings) 
• Out of date / improperly stored test strips (give false low readings) 
• Potential for error in low blood glucose range 
• Contamination of the sample may arise from substances present on the test-
finger:  
o Alcohol gel or wipes used to clean the finger 
o Newspaper print, perfumes, hand creams, hairspray, hair gel  
o Residues of food and drink  
(Dougherty and Lister, 2015; Hortensius et al 2011; Trend UK, 2017) 
Any blood glucose measurement which does not correlate with the persons clinical 
presentation should be re-checked with consideration of potential sources of error.  
Interferences and contraindications to finger prick testing are detailed in table 4.  
 
Table 4: Contraindications / interferences in blood glucose testing:  
Contra-indication Example 
Dialysis treatment  Some fluids may contain Maltose which 
can interfere with test strip methodology 
Peripheral circulatory failure Severe dehydration, DKA, hypotension, 
shock, peripheral vascular disease 
Severe dehydration Vomiting or diarrhoea, diuretics, 
uncontrolled diabetes 
Variations in blood oxygen tension People receiving intensive oxygen 
therapy 
High concentrations of non-glucose 
reducing substances in the blood 
Intravenous infusion of ascorbic acid 
High bilirubin values Jaundice 
Extremes of haematocrit Neonatal blood samples, pregnancy 
Hyperlipdaemia Total parenteral nutrition, 
hyperlipidaemia 
Reference: MHRA (2013) 
Diabetes Monitoring and Management Technologies 
SMBG  and insulin dosing technologies are constantly developing and it is important 
to remain up to date regarding the technologies available, to ensure people living 
with diabetes are offered the most up to date and evidence based equipment and 
education to manage their blood glucose levels.  
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Smart meters  
Choosing the right meter and strips is dependent on a number of factors including 
availability, cost, individual suitability and prescribing restrictions. There are currently 
43 smart meters currently on the market (Diabetes UK 2020b). Modern smart meters 
have the capability to record up to 1000 readings and provide 30, 60 or 90 day data 
averages with optional data download. A number of meters have an integrated finger 
prick lancet and some can also test for ketones.  
Rationalisation of the provision of meters and strips in some areas has led to 
challenges in accessing the necessary equipment to SMBG for some individuals living 
with diabetes. Diabetes UK (2017a) highlights that it is essential that people are 
prescribed sufficient SBGM testing strips for their clinical need. This enables people 
with diabetes to self-manage, including understanding ‘sick day rules’, recognising the 
symptoms of DKA / HSS, early action and how to seek help, and any specific 
considerations in light of any job they may carry out, especially if it involves driving. In 
light of this, DUK have compiled an advocacy pack to assist people with diabetes to 
get the right equipment for their needs https://www.diabetes.org.uk/resources-
s3/2017-09/1092C_Test_strips_advocacy%20report_WEB.pdf.   
Insulin Pens 
Insulin pens are designed to be easy to use and are either disposable or reusable with 
accompanying cartridges. There are a huge variety of insulin pens available, some of 
which have smart functionality enabling the following:  
• Record date and time of insulin dosing 
• Record dose administered 
• Can deliver half-unit dosing 
• Pen cap can inform the user of time since last dose 
• Can interface with smart devices such as smart phones 
Continuous glucose monitoring (CGM)/ flash blood glucose monitoring 
(flashGM):  
Technologies are available which now enable people with diabetes to continuously 
monitor and manage their blood glucose. Result can be reviewed via scanners or 
connected smart devices without the need for painful finger-prick testing  (Leelarathna 
and Wilmot, 2018, Yoo et al., 2008, Diabetes UK, 2017b) providing glucose readings 
with accompanying trend arrows (Messer et al., 2018) via an implanted device.  
FlashGM measures glucose levels within interstitial fluid, utilising a sensor applied to 
the skin and a reader; an optional companion app for mobile devices is also available. 
The sensor remains in place for 14 days (NICE, 2017). Whilst some research classifies 
flashGM under the umbrella term ‘continuous glucose monitoring’ (CGM) because the 
device records continuously (Blum, 2018), it should be noted that the data is not 
transmitted continuously. FlashGM is sometimes classified as ‘intermittently viewed 
continuous glucose monitoring’ (iCGM). Other devices are available which do provide 
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‘real-time’ CGM (rtCGM) with continuous data transmission which also give 
accompanying alarm warnings, a feature that flashGM does not have. Both rtCGM 
and flashGM facilitate monitoring of time spent in target glucose range, however, with 
flashGM these trends can only be observed after physically scanning the sensor 
(Danne et al., 2017).   
The Abbot Freestyle Libre is a form of flashGM which has been shown to reduce time 
spent in hypo / hyperglycaemia and improves time in glucose range (Campbell et al., 
2018). Further, Tyndall et al. (2019) have demonstrated flashGM confers significant 
improvements in HbA1c (HbA1c being an indicator of glucose control over preceding 
12 weeks). Recent evaluations in a ‘real world’ sample by Dunn et al. (2018) 
demonstrated that higher rates of scanning using flashGM are associated with 
improvements to markers of glycaemic control related to time in blood glucose target 
range. Daily costs are lower compared with rtCGM systems and calibration is not 
required as it is with rtCGM (Petrie, Peters, Bergenstal et al., 2017). 
In November 2017, the Abbott Freestyle Libre continuous glucose monitor device was 
made available through the NHS formulary for people with T1DM who meet specific 
NHS England criteria. The device continuously measures glucose levels within 
interstitial fluid, utilising a sensor applied to the skin (NICE, (2017). These devices will 
become increasingly prevalent in coming years.  
Insulin pumps 
Insulin pumps are battery operated devices that provide a person with regular insulin 
delivered via a small sub-cut cannula. The delivery cannula remains in situ for 2-3 
days. Extra insulin is delivered via “bolus dosing” when the individual is carbohydrate 
counting. Insulin pumps are not recommended by NICE for people with type 2 
diabetes. They are recommended for individuals under 12 years if multiple daily 
injections (MDI) are considered impractical or inappropriate. Children would be 
expected to undergo a trial of MDI between age 12 and 18 for continuing access to 
this technology.  
Insulin pumps are recommended for adults and children 12 years and over with type 
1 diabetes if the individual, in achieving HbA1c targets with MDI person is experiencing 
disabling hypos (repeated and unpredictable occurrence that results in anxiety and 
effects quality of life), or their HbA1c is 69 mmol/mol or above despite high level care 
with MDI and demonstrating commitment to control. They may be further indicated as 
a strategy for managing impaired awareness of hypoglycaemia (NICE, 2008).  
A full up to date resource of Medications and Kit by Diabetes UK (2020b) is 
available here https://cdn.shopify.com/s/files/1/1922/6045/files/diabetes-uk-meds-
and-kit-2020.pdf?883 
 
Closed Loop Artificial Pancreas 
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Increasingly, the online type 1 diabetes community are supporting one another in 
building DIY closed loop artificial pancreas systems (APS). These systems utilise 
existing technology (pumps and wearable sensors) alongside bespoke, wearable 
miniature computers with built in dosing algorithms to deliver continuous insulin and 
automated dosing adjustment. This means the user relies entirely on the insulin pump, 
sensor and algorithm to manage blood glucose levels automatically. 
Instructions for building these systems at home, alongside the dosing algorithms 
required, are freely available via the internet in open source format.  Devices used in 
DIY closed loop APS are used outside of their licensed purpose and also 
manufacturers warranty and those that use their devices in such a way, do so at their 
own risk. Such systems could potentially lead to hypo / hyper glycaemia and diabetic 
ketoacidosis (Diabetes UK, 2020c). 
The rise in such DIY systems has been driven not only by a supportive and connected 
online diabetes community, but is also borne out of the frustration experienced by 
people living with diabetes waiting for advancements in technology.  MedTech 
companies are developing similar devices but the time to market is still some way off. 
Users of such systems report more time in blood glucose range and less 
hypoglycaemia, with overall improved control. However there is currently no empirical 
research to support these findings.  
Although users of such devices are relatively few, numbers are growing. In light of this, 
Diabetes UK (2020c) has produced a position statement, endorsed by the Royal 
College of Nursing, in relation to DIY closed loop APS.  There has been concern from 
healthcare professionals that they risk legal or regulatory body actions in advising 
people in relation to using these off-license systems. The position statement 
recommends clinical rather than legal guidance and provides a number of 
recommendations regarding on-going clinical care, assessment of competence and 
appropriate documentation.  
Conclusion:  
All practice nurses should be familiar with the importance of blood glucose monitoring 
and the procedure to carry out testing safely and effectively in order to ensure people 
with diabetes are appropriately educated. Appropriate and timely monitoring of blood 
glucose will allow for the effective management of blood glucose levels, which fall out 
of target ranges. This will ensure ongoing safety during episodes of acute illness and 
effective management of diabetes mellitus in the longer term, minimising serious 
diabetic related health complications.  
The development of technologies will empower people living with diabetes to be further 
engaged in their disease management and nurses must ensure they maintain their 
knowledge in relation to this dynamic area of healthcare.  
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